CN Patent

CN109661393A — 帕布昔利布的新晶型及其制备方法及其用途

Assigned to Shanghai Begreat Pharmatech · Expires 2019-04-19 · 7y expired

What this patent protects

本发明公开了6‑乙酰基‑8‑环戊基‑5‑甲基‑2‑(5‑哌嗪‑1‑基‑吡啶‑2‑基氨基)‑8H‑吡啶并[2，3‑d]嘧啶‑7‑酮的新多晶型I、II、III、IV、V、VI、VII、VIII、IX、X、XI、XII和XIV及其制备方法和药用用途。晶型VIII为半水合物晶型，与现有晶型相比，新晶型在溶解度、稳定性和制备工艺方面具有明显优势。

USPTO Abstract

本发明公开了6‑乙酰基‑8‑环戊基‑5‑甲基‑2‑(5‑哌嗪‑1‑基‑吡啶‑2‑基氨基)‑8H‑吡啶并[2，3‑d]嘧啶‑7‑酮的新多晶型I、II、III、IV、V、VI、VII、VIII、IX、X、XI、XII和XIV及其制备方法和药用用途。晶型VIII为半水合物晶型，与现有晶型相比，新晶型在溶解度、稳定性和制备工艺方面具有明显优势。

Drugs covered by this patent

Patent Metadata

Patent number
CN109661393A
Jurisdiction
CN
Classification
—
Expires
2019-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Begreat Pharmatech
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.